August 1, 2023

Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD Results support the continued development of obexelimab for the treatment of IgG4-RD and potentially other B cell-mediated autoimmune conditions WALTHAM,

CONTINUE READING

Rhino killings decrease by 11%

In the first six months of this year, 231 rhinos were killed in South Africa, representing an 11% decrease when compared to the same period last year.This represents a decline of 28 animals killed for their horn.Addressing a media

CONTINUE READING
latest Posts